New Technology– category –
-
CB1R Molecular Glue Degraders: Cancer Therapy Strategy for 2026
npj Drug Discovery Overview Researchers have developed covalent molecular glue degraders, specifically MG-CB2, to reduce the abundance of cannabinoid receptor type 1 (CB1R) in cancer cells. The approach targets the ubiquitin-proteasome s... -
JNJ-6143: Phase 1 results for RIPTAC in advanced prostate cancer
AOL USA Overview Johnson & Johnson reported a 75% complete or partial tumor response rate in patients with advanced prostate cancer treated with JNJ-6143. The once-daily oral molecule demonstrated significant PSA reductions in patien... -
Sacituzumab Tirumotecan: Survival Gains in Recurrent Endometrial Cancer
Inside Precision Medicine USA Overview Sacituzumab tirumotecan (sac-TMT) significantly extended overall survival to 19.0 months compared to 12.1 months for conventional chemotherapy in patients with advanced or recurrent endometrial canc... -
FDA Gene Therapy Guidance: Expediting Personalized BLA Approvals
BioSpace USA Overview The FDA and CMS have introduced a draft guidance allowing a single Biologics License Application (BLA) to cover multiple personalized gene therapy variants. This framework, combined with the expansion of the CMS Cel... -
Ascletis ASC30: Phase II Results for Oral GLP-1 in Type 2 Diabetes
BioPharma APAC China Overview Ascletis Pharma's oral small molecule GLP-1 receptor agonist, ASC30, achieved a placebo-adjusted HbA1c reduction of up to 1.7% and weight loss of up to 4.4% in a U.S. Phase II trial for type 2 diabetes. The ... -
AZD8205: B7-H4 ADC Phase 1/2a results for solid tumors
BIOENGINEER.ORG USA Overview The first-in-human BLUESTAR trial of the B7-H4-directed antibody-drug conjugate AZD8205 (puxitatug samrotecan) demonstrated partial tumor responses in patients with advanced ovarian, endometrial, and breast c... -
CAMOLE-1: ML-driven discovery of selective MMP12 inhibitors
bioRxiv USA Overview Calico Life Sciences developed CAMOLE-1, a machine learning platform that utilizes an all-atom diffusion model to design potent and selective peptide inhibitors. The system successfully optimized an MMP12 inhibitor o... -
Light-Responsive LNPs: VEGFA Editing for CNV Suppression
bioRxiv Overview Researchers developed a light-responsive lipid nanoparticle (LNP) platform to deliver Cas9 RNP for the spatially controlled editing of the VEGFA gene. In a rat model of choroidal neovascularisation (CNV), a single intrav... -
LNP Morphology: Impact of Shape on mRNA Transfection Performance
bioRxiv Overview Research indicates that the shape and internal architecture of lipid nanoparticles (LNP) significantly determine the magnitude and duration of mRNA transfection. Non-spherical, vesicular morphologies exhibit substantiall... -
PAK BioSolutions: Integrated Continuous AAV8 Purification Specs
PR Newswire（PAK BioSolutions） USA Overview PAK BioSolutions and iBET have demonstrated a continuous purification process for AAV8 that achieves 79% full-capsid enrichment over 12 hours of operation. The study proves that integrated cap...
